(Q40505474)

English

Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV).

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV). (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Robert F. Garry

4

object named as

Robert F Garry

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

author name string

Bruno Sainz

1

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Eric C Mossel

2

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

C J Peters

3

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

language of work or name

0 references

publication date

1 November 2004

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

number of pages

7

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

329

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

11-17

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Inhibition of different Lassa virus strains by alpha and gamma interferons and comparison with a less pathogenic arenavirus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.08.011

7 January 2021

Treatment of SARS with human interferons

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.08.011

7 January 2021

Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.08.011

7 January 2021

Identification of a novel coronavirus in patients with severe acute respiratory syndrome

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.08.011

7 January 2021

Current concepts in SARS treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.08.011

7 January 2021

Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.08.011

7 January 2021

Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.08.011

7 January 2021

Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.08.011

7 January 2021

Interferon-beta 1a and SARS coronavirus replication

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.08.011

7 January 2021

A novel coronavirus associated with severe acute respiratory syndrome

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.08.011

7 January 2021

Synergistic antiviral activity of human interferon combinations in the hepatitis C virus replicon system

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.08.011

7 January 2021

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.08.011

7 January 2021

Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.08.011

7 January 2021

Coronavirus as a possible cause of severe acute respiratory syndrome

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.08.011

7 January 2021

Alpha/Beta interferon and gamma interferon synergize to inhibit the replication of herpes simplex virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.08.011

7 January 2021

The antiviral effect of interferon-beta against SARS-coronavirus is not mediated by MxA protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.08.011

7 January 2021

Severe acute respiratory syndrome-related coronavirus is inhibited by interferon- alpha

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.08.011

7 January 2021

SARS-related virus predating SARS outbreak, Hong Kong

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.08.011

7 January 2021

What is synergy?

1 reference

https://pubmed.ncbi.nlm.nih.gov/15476870

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15476870

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.VIROL.2004.08.011

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40505474&oldid=1771982322"